Status:
TERMINATED
Study Evaluating Vaccine in Adults With HIV
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
HIV Infections
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs that are used to help immune response) have an acceptable safety profile in treating individuals with HIV. ...
Eligibility Criteria
Inclusion
- Must be HIV positive.
- Receiving stable HAART for a minimum of 6 consecutive months immediately before screening.
- CD4 T-cell count greater than 350 mm cubed/mL at time of screening and no reported CD4 T-cell count less than 250 mm cubed/mL at any time before screening.
- Other Inclusions Apply
Exclusion
- Any chronic symptomatic infection other than HIV.
- History of diagnosed autoimmune disease (currently active or under control).
- Use of any prior HIV vaccine (prophylactic and/or therapeutic) within one year before or during screening (documented, unblinded placebo recipients from previous clinical trials may participate without this time restriction).
- Other Exclusions Apply
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2007
Estimated Enrollment :
91 Patients enrolled
Trial Details
Trial ID
NCT00195312
Start Date
August 1 2005
End Date
August 1 2007
Last Update
December 5 2007
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35294
2
Denver, Colorado, United States, 80262
3
Orlando, Florida, United States, 32803
4
Boston, Massachusetts, United States, 02215